Clinical trials: Elevated Blood Pressure
Pulmonary Arterial Hypertension
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).
- Trial name
- RESTORE (NCT04435782)
- Testing
- JNJ-67896049
- Where
- 35 sites in United States, Argentina and 13 more
- Volunteers
- 9 people
- Sponsor
- Actelion
Hypertension
Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients.
- Trial name
- ASCENT (NCT00942994)
- Testing
- Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
- Where
- 5 sites in United States
- Volunteers
- 412 people
- Sponsor
- Novartis
Hypertension
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.
- Trial name
- NCT00396656
- Testing
- Atenolol, Hydrochlorothiazide (HCTZ)), Valsartan
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 30 people
- Sponsor
- Novartis
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
HIV/AIDS, Hypertension
Systems Analysis and Improvement Approach for the Hypertension Care Cascade
As undiagnosed and untreated hypertension is one of the largest drivers of cardiovascular disease in sub-Saharan Africa approaches are needed to optimize the hypertension care cascade.
- Trial name
- SAIA-HTN (NCT04088656)
- Testing
- Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization
- Where
- 16 sites in Mozambique
- Volunteers
- 305 people
- Sponsor
- University of Washington
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers.
- Trial name
- NCT00716742
- Testing
- bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
- Where
- United States
- Volunteers
- 1,099 people
- Sponsor
- Allergan
Open-angle Glaucoma, Ocular Hypertension
Adherence Assessment With Travalert Dosing Aid
The purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004% and timolol 0.5% using the Travalert® device.
- Trial name
- NCT00508469
- Testing
- Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav), Travoprost 0.004% eye drops, Timolol 0.05% eye drops
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Alcon Research
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446459
- Testing
- mycophenolate mofetil (CellCept)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
Hypertension, Blood Pressure
IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN
The purpose of this post market clinical investigation is to further evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with uncontrolled hypertension.
- Trial name
- EnligHTN-II (NCT01705080)
- Testing
- EnligHTN
- Where
- 33 sites in Australia, France and 9 more
- Volunteers
- 276 people
- Sponsor
- Abbott Medical Devices
Hypertension
Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
The primary objective of this study was to assess the anti-hypertensive effect of OM/HCTZ 40/12.5 mg combination therapy compared to OM 40 mg monotherapy in lowering sitting diastolic BP in hypertensive patients after 8 weeks of…
- Trial name
- NCT00441350
- Testing
- OM 40, OM/HCTZ 40/12.5
- Where
- 65 sites in Croatia, Czechia and 6 more
- Volunteers
- 1,004 people
- Sponsor
- Menarini Group
Hypertension
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
- Trial name
- ATTAIN (NCT00772577)
- Testing
- Aliskiren Hydrochlorothiazide, Ramipril
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2, Hypertension
Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
MK-8835-042 (B1521004) is designed to assess the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729), in participants with type 2 diabetes and hypertension.
- Trial name
- NCT01096667
- Testing
- Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg
- Volunteers
- 194 people
- Sponsor
- Merck Sharp & Dohme LLC
Mood Disorders, Hypertension
One-Day Acceptance and Commitment Training Intervention in Primary Care Patients
The goal of this study is to 1) examine the feasibility and acceptability of a one-day Acceptance and Commitment Training + Illness Management (ACT-IM) intervention in patients with comorbid vascular disease risk factors and…
- Conditions
- Mood Disorders, Hypertension, Diabetes, Hypercholesterolemia
- Trial name
- NCT01879800
- Testing
- Acceptance and Commitment Therapy plus Illness Management
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Lilian N. Dindo
Hypertension, Renal
RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension
The RENABLATE feasibility study is a prospective, multi-center, non-randomized feasibility study to evaluate the safety and effectiveness of the investigational multi-electrode ablation catheter and integrated ablation system to…
- Trial name
- NCT01756300
- Testing
- Celsius® ThermoCool® RD
- Volunteers
- 35 people
- Sponsor
- Biosense Webster, Inc.
Hypertension
Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity
Pharmacokinetics of Tacrolimus and Sirolimus alone and in combination in liver transplant recipients.
- Trial name
- Sirolimus (NCT01709136)
- Testing
- Sirolimus
- Volunteers
- 3 people
- Sponsor
- University of Pittsburgh
Hypertension
Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients
- Trial name
- NCT00879411
- Testing
- Micardis
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension
REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year.
- Trial name
- REPAIR (NCT02310672)
- Testing
- Macitentan
- Where
- 41 sites in United States, Australia and 10 more
- Volunteers
- 89 people
- Sponsor
- Actelion
Glaucoma, Open-Angle
Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)
First, to compare safety and effectiveness outcomes for canaloplasty and trabeculotomy using the OMNI Surgical System to implantation of the iStent inject in lowering intraocular pressure (IOP) in pseudophakic eyes with open…
- Trial name
- NCT04658095
- Testing
- Canaloplasty and trabeculotomy with the OMNI system., iStent inject, Canaloplasty
- Where
- 5 sites in Germany, Spain and 1 more
- Volunteers
- 10 people
- Sponsor
- Sight Sciences, Inc.
Weight Loss, Postpartum Weight Retention
Postpartum Weight Loss for Women at Elevated Cardiovascular Risk
The aim of this study is to test the feasibility and effectiveness of a 16-week online behavioral weight loss program compared to usual care to promote weight loss in the postpartum period among women with cardiovascular risk…
- Conditions
- Weight Loss, Postpartum Weight Retention, Hypertension in Pregnancy, Diabetes Mellitus in Pregnancy
- Trial name
- EMPOWER-Mom (NCT04914819)
- Testing
- Online Behavioral Weight Loss Program, Virtual weigh-in
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- University of Pennsylvania
Glaucoma, Open-Angle
A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma
To prospectively assess the clinical effect of ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System in pseudophakic eyes on intraocular pressure (IOP) and the use of IOP-lowering…
- Trial name
- ORION (NCT04465630)
- Testing
- OMNI® Surgical System
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- Sight Sciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.